Stephen Salloway

59.6k total citations · 12 hit papers
180 papers, 13.9k citations indexed

About

Stephen Salloway is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Stephen Salloway has authored 180 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Psychiatry and Mental health, 87 papers in Physiology and 32 papers in Pharmacology. Recurrent topics in Stephen Salloway's work include Dementia and Cognitive Impairment Research (93 papers), Alzheimer's disease research and treatments (85 papers) and Cholinesterase and Neurodegenerative Diseases (30 papers). Stephen Salloway is often cited by papers focused on Dementia and Cognitive Impairment Research (93 papers), Alzheimer's disease research and treatments (85 papers) and Cholinesterase and Neurodegenerative Diseases (30 papers). Stephen Salloway collaborates with scholars based in United States, United Kingdom and Sweden. Stephen Salloway's co-authors include Kaj Blennow, Bart De Strooper, Giovanni B. Frisoni, Philip Scheltens, Wiesje M. van der Flier, Monique M.B. Breteler, Paul Malloy, Jeffrey L. Cummings, Reisa A. Sperling and Paul Aisen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and NeuroImage.

In The Last Decade

Stephen Salloway

175 papers receiving 13.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alzheimer's disease

2016 2.4k citations Stephen Salloway et al. profile →
Donanemab in Early Alzheimer’s Disease

2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression

2008 631 citations Paul Malloy, Stephen Salloway et al. profile →
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

2021 598 citations Gil D. Rabinovici, Stephen Salloway et al. profile →
Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience

2008 532 citations Paul Malloy, Stephen Salloway et al. profile →
Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder

2006 519 citations Paul Malloy, Stephen Salloway et al. profile →
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

2021 411 citations Stephen Salloway, Frederik Barkhof et al. JAMA Neurology profile →
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

2022 307 citations Oskar Hansson, Adam L. Boxer et al. Alzheimer s & Dementia profile →
Aducanumab: Appropriate Use Recommendations

2021 207 citations Paul Aisen, Liana G. Apostolova et al. The Journal of Prevention of Alzheimer s Disease profile →
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

2021 155 citations Jeffrey L. Cummings, Paul Aisen et al. profile →
Aducanumab: Appropriate Use Recommendations Update

2022 126 citations Jeffrey L. Cummings, Gil D. Rabinovici et al. The Journal of Prevention of Alzheimer s Disease profile →
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease

2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology profile →

Peers

Countries citing papers authored by Stephen Salloway

Since Specialization

Citations

This map shows the geographic impact of Stephen Salloway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Salloway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Salloway more than expected).

Fields of papers citing papers by Stephen Salloway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Salloway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Salloway. The network helps show where Stephen Salloway may publish in the future.

Co-authorship network of co-authors of Stephen Salloway

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Salloway. A scholar is included among the top collaborators of Stephen Salloway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Salloway. Stephen Salloway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease 2025 ·The Journal of Prevention of Alzheimer s Disease ·Eric Siemers, (unknown), Gopalan Sethuraman, Karen Sundell, Vladimir Skljarevski, Erika N. Cline, Hao Zhang, Jasna Jerecı̀ć, Lawrence S. Honig, Stephen Salloway, Reisa A. Sperling, Mirjam N. Trame, Michael Dodds, (unknown)	4
2	Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force 2025 ·The Journal of Prevention of Alzheimer s Disease ·Davide Angioni, Lefkos Middleton, Randall J. Bateman, Paul Aisen, Adam L. Boxer, (unknown), Jing Zhou, Irene Gerlach, Rema Raman, Howard Fillit, Stephen Salloway, Reisa Sperling, Bruno Vellas, (unknown)	2
3	The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 2025 ·The Journal of Prevention of Alzheimer s Disease ·Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, (unknown), Stephen Salloway, Mark A. Mintun, John R. Sims	2
4	Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab 2024 ·Alzheimer s & Dementia ·Tianle Chen, John O’Gorman, Carmen Castrillo‐Viguera, Rajasimhan Rajagovindan, (unknown), Ying Tian, (unknown), Philipp von Rosenstiel, Christian von Hehn, Stephen Salloway, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock, Priya Singhal	11
5	Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults 2024 ·Journal of the International Neuropsychological Society ·Louisa I. Thompson, Alyssa N. De Vito, Zachary J. Kunicki, Sheina Emrani, (unknown), (unknown), Karra Harrington, Nelson Roque, (unknown), Stephen Salloway, Stephen Correia, Richard N. Jones, Martin J. Sliwinski	4
6	1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial 2024 ·Age and Ageing ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, (unknown), C D Evans, Ming‐Chi Lu, Paul Ardayfio, Janet D. Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, (unknown), Ellen B. Dennehy, Doug A. Brooks, Daniel Skovronsky, (unknown), (unknown)	2
7	Alzheimer’s Disease — Managing Stages of Dementia 2024 ·New England Journal of Medicine ·Nathaniel A. Chin, (unknown), (unknown), Betsy McAlister Groves, (unknown), Dan R. Johnson, (unknown), (unknown), Allan H. Ropper, Stephen Salloway, (unknown), (unknown), (unknown)	5
8	Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease 2024 ·JAMA Neurology ·Stephen Salloway, (unknown), Nicola Voyle, Christopher Lane, Gregory Klein, (unknown), Simona Rossomanno, (unknown), Szofia Bullain, Frederik Barkhof, Tobias Bittner, (unknown), (unknown), Roxana Aldea, Merçé Boada, Janice Smith, Rachelle S. Doody	15
9	Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies 2024 ·Alzheimer s & Dementia ·Pierre N. Tariot, Marie‐Emmanuelle Riviere, Stephen Salloway, Jeffrey M. Burns, Jón Snædal, Beth Borowsky, (unknown), Fonda Liu, Marie‐Laure Rouzade‐Dominguez, Pilar Cazorla, (unknown), Michał Arkuszewski, (unknown), Vissia Viglietta, (unknown), Angelika Caputo, Jessica B. Langbaum, (unknown), Ana Graf	6
10	Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial 2023 ·Alzheimer s & Dementia ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, Jennifer A. Zimmer, Cynthia Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Ellen B. Dennehy, Dawn A. Brooks, Daniel Skovronsky	6
11	Developments in understanding early onset Alzheimer's disease 2023 ·Alzheimer s & Dementia ·Percy Griffin, Liana G. Apostolova, Bradford C. Dickerson, Gil D. Rabinovici, Stephen Salloway, (unknown), Joseph C. Masdeu, Dustin B. Hammers, Srilatha Raghuram, Stephen E. Hall, María C. Carrillo	11
12	Remote and in‐clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults 2023 ·Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring ·Louisa I. Thompson, Zachary J. Kunicki, Sheina Emrani, (unknown), Alyssa N. De Vito, (unknown), Catherine Dion, Karra Harrington, Nelson Roque, Stephen Salloway, Martin J. Sliwinski, Stephen Correia, Richard N. Jones	16
13	91 Remote Smartphone-Based Assessment Predicts Standard Neuropsychological Test Performance and Cerebral Amyloid Status in Cognitively Normal Older Adults 2023 ·Journal of the International Neuropsychological Society ·Louisa I. Thompson, (unknown), Sheina Emrani, Alyssa N. De Vito, Karra Harrington, Nelson Roque, Stephen Salloway, Martin J. Sliwinski, Stephen Correia	1
14	Donanemab in Early Alzheimer’s Disease breakdown → 2021 ·New England Journal of Medicine ·Mark A. Mintun, Albert Lo, Cynthia Evans, Alette M. Wessels, Paul Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Mirosław Bryś, Liana G. Apostolova, Stephen Salloway, Daniel Skovronsky	969
15	Advancing combination therapy for Alzheimer's disease 2020 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Stephen Salloway, (unknown), Kumar Budur, (unknown), Ronald B. DeMattos, Philipp von Rosenstiel, Antonio Páez, Rebecca Evans, Christopher J. Weber, James A. Hendrix, Susan Worley, Lisa J. Bain, María C. Carrillo	42
16	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning 2020 ·Information Fusion ·Diego Castillo-Barnés, Li Su, Javier Ramı́rez, D. Salas-González, Francisco J. Martínez-Murcia, I. Álvarez, F. Segovia, Andrés Ortíz, Carlos Cruchaga, Martin R. Farlow, Chengjie Xiong, N. R. Graff-Radford, Peter R. Schofield, Colin L. Masters, Stephen Salloway, Mathias Jucker, Hiroshi Mori, Johannes Levin, J. M. Górriz, (unknown)	15
17	Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes 2019 ·Journal of the International Neuropsychological Society ·Breton M. Asken, Kelsey R. Thomas, Athene Lee, Jennifer Davis, Paul Malloy, Stephen Salloway, (unknown)	3
18	Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) 2016 ·Neurology ·Vissia Viglietta, John O’Gorman, Leslie Williams, Ying Tian, Alfred Sandrock, Rachelle S. Doody, Stephen Salloway, Frederik Barkhof, Bruno Vellas, Mary Sano, Paul Aisen, Jeffrey Sevigny	9
19	Alzheimer disease: Time to improve its diagnosis and treatment 2009 ·Cleveland Clinic Journal of Medicine ·Stephen Salloway, Stephen Correia	52
20	The neuropsychiatry of limbic and subcortical disorders 1997 ·Stephen Salloway, Paul Malloy, Jeffrey L. Cummings	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact